Table 1.
Characteristics of the Study Population
| Characteristics |
Subset N = 265 |
Other HCCS Participants N = 847 |
P a |
|---|---|---|---|
| Age at participation (mean ± SD), y | 56.0 (10.6) | 60.6 (12.3) | <.01 |
| Age at diagnosis (mean ± SD), y | 53.7 (10.3) | 57.2 (12.2) | <.01 |
| Sex | |||
| Male | 137 (51.7) | 465 (54.9) | .36 |
| Female | 128 (48.3) | 382 (45.1) | |
| Birth country | |||
| United States | 46 (19.1) | 318 (38.6) | <.01 |
| Mexico | 126 (52.3) | 372 (45.1) | |
| Other | 69 (28.6) | 134 (16.3) | |
| BMI (mean ± SD) | 30.5 ± 6.6 | 31.0 ± 14.2 | .40 |
| Physical activity | |||
| No | 76 (31.7) | 230 (28.0) | .26 |
| Yes | 164 (68.3) | 593 (72.0) | |
| Alcohol use | |||
| <1 per wk | 111 (45.9) | 337 (40.6) | .14 |
| ≥1 per wk | 131 (54.1) | 493 (59.4) | |
| Tobacco use | |||
| Never | 142 (59.2) | 451 (54.6) | .21 |
| Ever | 98 (40.8) | 375 (45.4) | |
| Mean pack per y ± SD | 20.5 ± 84.0 | 14.6 ± 25.5 | .51 |
| NSAID use | |||
| Never | 127 (52.7) | 434 (52.0) | .84 |
| Ever | 114 (47.3) | 401 (48.0) | |
| Hormone replacement therapy | |||
| Never | 109 (90.1) | 291 (78.2) | <.01 |
| Ever | 12 (9.9) | 81 (21.8) | |
| Contraceptive use | |||
| Never | 46 (38.3) | 160 (42.7) | .40 |
| Ever | 74 (61.7) | 215 (57.3) | |
| Diabetes | |||
| No | 184 (76.0) | 586 (69.9) | .08 |
| Yes | 58 (24.0) | 252 (30.1) | |
| Crohn disease | |||
| No | 238 (99.6) | 827 (99.3) | .51 |
| Yes | 1 (0.4) | 6 (0.7) | |
| Ulcerative colitis | |||
| No | 239 (97.6) | 797 (95.6) | .16 |
| Yes | 6 (2.4) | 37 (4.4) | |
| Familial adenomatous polyposis | |||
| No | 234 (98.7) | 804 (97.9) | .59 |
| Yes | 3 (1.3) | 17 (2.1) | |
| History of polyps | |||
| No | 140 (59.3) | 338 (41.1) | <.01 |
| Yes | 96 (40.7) | 484 (58.9) | |
| Family history | |||
| First‐degree relative with CRC | |||
| No | 231 (87.2) | 725 (88.3) | .62 |
| Yes | 34 (12.8) | 96 (11.7) | |
| Second‐degree relative with CRC | |||
| No | 250 (94.3) | 444 (92.5) | .34 |
| Yes | 15 (5.7) | 36 (7.5) | |
| Cancer localization | |||
| Localized | 46 (31.3) | 342 (44.7) | <.01 |
| Regional | 64 (43.5) | 366 (47.8) | |
| Metastatic | 37 (25.2) | 57 (7.5) | |
| Tumor location | |||
| Proximal colon | 69 (27.1) | 223 (26.6) | .28 |
| Distal colon | 72 (28.2) | 279 (33.3) | |
| Rectum | 114 (44.7) | 336 (40.1) | |
| Histologic differentiation | .28 | ||
| Well | 12 (9.0) | 74 (10.4) | |
| Moderate | 95 (71.4) | 539 (76.0) | |
| Poor | 25 (18.8) | 89 (12.6) | |
| Undifferentiated | 1 (0.8) | 7 (1.0) |
Abbreviations: BMI, body mass index; CRC, colorectal cancer; HCCS, Hispanic Colorectal Cancer Study; NSAID, nonsteroidal anti‐inflammatory drug; SD, standard deviation.
a
P values were derived from the Student t test for continuous variables and the chi‐square/Fisher exact test for categorical variables.